Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) have been given an average recommendation of “Moderate Buy” by the twenty-six brokerages that are covering the company, MarketBeat reports. Six equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have assigned a strong buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $463.1326.

Several research firms have recently weighed in on ALNY. Royal Bank Of Canada decreased their price target on shares of Alnylam Pharmaceuticals from $450.00 to $445.00 and set an “outperform” rating for the company in a research note on Friday, May 1st. HC Wainwright reaffirmed a “buy” rating and set a $510.00 price target on shares of Alnylam Pharmaceuticals in a research note on Thursday, June 4th. Truist Financial decreased their price target on shares of Alnylam Pharmaceuticals from $515.00 to $505.00 and set a “buy” rating for the company in a research note on Monday, April 13th. Chardan Capital reaffirmed a “buy” rating and set a $425.00 price target on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 25th. Finally, Wells Fargo & Company lifted their price target on shares of Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the company an “equal weight” rating in a research note on Friday, May 1st.

Insider Activity at Alnylam Pharmaceuticals

In other news, insider Melissa Mclaughlin sold 2,286 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $330.42, for a total transaction of $755,340.12. Following the completion of the sale, the insider owned 9,443 shares of the company’s stock, valued at approximately $3,120,156.06. The trade was a 19.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director David E. I. Pyott sold 3,830 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the transaction, the director directly owned 1,582 shares of the company’s stock, valued at $473,302.76. This trade represents a 70.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 7,740 shares of company stock valued at $2,420,214 in the last ninety days. Insiders own 0.86% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Large investors have recently bought and sold shares of the business. MV Capital Management Inc. bought a new position in Alnylam Pharmaceuticals in the fourth quarter worth approximately $25,000. Caitong International Asset Management Co. Ltd bought a new position in Alnylam Pharmaceuticals in the third quarter worth approximately $29,000. HM Payson & Co. purchased a new position in Alnylam Pharmaceuticals in the fourth quarter worth $27,000. Ameriflex Group Inc. purchased a new position in Alnylam Pharmaceuticals in the third quarter worth $32,000. Finally, Golden State Wealth Management LLC grew its holdings in Alnylam Pharmaceuticals by 100.0% in the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 36 shares during the last quarter. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY opened at $278.09 on Friday. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.13 and a quick ratio of 3.06. The company has a market cap of $37.13 billion, a P/E ratio of 75.98 and a beta of 0.29. Alnylam Pharmaceuticals has a 1 year low of $273.11 and a 1 year high of $495.55. The firm has a 50-day simple moving average of $300.18 and a two-hundred day simple moving average of $338.11.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, beating the consensus estimate of $0.87 by $1.12. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The firm had revenue of $1.17 billion during the quarter, compared to the consensus estimate of $1.12 billion. During the same quarter in the previous year, the firm posted ($0.44) earnings per share. The company’s revenue was up 96.4% on a year-over-year basis. Research analysts anticipate that Alnylam Pharmaceuticals will post 7.47 earnings per share for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.